首页|胃舒宁联合泮托拉唑对十二指肠溃疡患者临床治疗及血清学指标的影响

胃舒宁联合泮托拉唑对十二指肠溃疡患者临床治疗及血清学指标的影响

扫码查看
目的 研究胃舒宁联合泮托拉唑对十二指肠溃疡患者临床治疗及血清学指标的影响.方法 选择2019年1月-2023年1月的100例十二指肠溃疡患者进行本次研究,按照随机数表法分为研究组53例和对照组47例,对照组采用泮托拉唑治疗,研究组采用胃舒宁联合泮托拉唑治疗.对比两组总有效率,治疗后临床症状(反酸、腰痛、烧心)改善时间,治疗前后血清学指标TGF-α、IL-8、NO、NF-κB水平,胃黏膜功能(GAS、PG-Ⅰ、PG-Ⅱ)指标.结果 治疗后,研究组总有效率显著高于对照组[93.34%(50/53)vs78.72%(37/47)](P<0.05);研究组反酸改善时间、腰痛改善时间、烧心改善时间均显著短于对照组[(2.03±0.20)d vs(3.18±0.26)d,(1.67±0.28)d vs(3.29±0.37)d,(2.09±0.31)d vs(3.80±0.42)d](P<0.05);研究组 TGF-α、IL-8、NF-κB 水平均显著低于对照组[(36.01±3.29)ng/L vs(47.23±3.97)ng/L,(12.29±3.12)ng/L vs(20.86±3.97)ng/L,(12.98±3.06)ng·L-1 vs(27.09±4.21)ng·L-1](P<0.05);NO 水平显著高于对照组(86.70±8.92)μmmol/L vs(56.39±7.03)μmmol/L(P<0.05);GAS、PG-Ⅰ、PG-Ⅱ 水平均显著低于对照组[(29.61±6.39)mg/mL vs(56.20±7.62)mg/mL,(61.58±15.80)ng/mL vs(83.29±18.62)ng/mL,(23.60±3.85)ng/mL vs(39.67±5.62)ng/mL](P<0.05).结论 胃舒宁联合泮托拉唑可有效改善十二指肠溃疡患者的临床症状,改善胃黏膜功能及血清学指标,治疗效果显著.
Effect of Weishuning(胃舒宁)Combined with Pantoprazole on Clinical Treatment and Serological Indexes of Patients with Duodenal Ulcer
Objective To study the effect of Weishuning(胃舒宁)combined with pantoprazole on clinical treatment and sero-logical indexes of patients with duodenal ulcer.Methods A hundred patients with duodenal ulcer who received treatment in the hospital from January 2019 to January 2023 were selected for this study.According to random number table method,they were di-vided into study group(53 cases)and control group(47 cases).The control group was treated with pantoprazole and the study group was treated with Weishuning combined with pantoprazole.The total effective rates of the two groups,the improvement time of clinical symptoms(acid reflux,low back pain,heartburn)after treatment,the levels of serum indicators[transforming growth factor-α(TGF-α),interleukin-8(IL-8),nitric oxide(NO),nuclear transcription factor kappa B(NF-κB)],gastric mucosa func-tion[gastrin(GAS),pepsinogen-Ⅰ(PG-Ⅰ),pepsinogen-Ⅱ(PG-Ⅱ)]before and after treatment were compared between the two groups.Results After treatment,the total effective rate of the observation group was significantly higher than that of the control group[93.34%(50/53)vs 78.72%(37/47)](P<0.05).The improvement time for acid reflux,low back pain and heartburn in the study group were significantly shorter than those in the control group[(2.03±0.20)d vs(3.18±0.26)d,(1.67±0.28)d vs(3.29±0.37)d,(2.09±0.31)d vs(3.80±0.42)d](P<0.05).The levels of TGF-α,IL-8,NO and NF-κB in the observation group were significantly lower than those of the control group[(36.01±3.29)ng/L vs(47.23±3.97)ng/L,(12.29±3.12)ng/L vs(20.86±3.97)ng/L,(12.98±3.06)ng·L-1 vs(27.09+4.21)ng·L-1](P<0.05).The NO level in the observation group was significantly higher than that of the control group[(86.70±8.92)μmmol/L vs(56.39±7.03)μmmol/L](P<0.05).The levels of GAS,PG-Ⅰ and PG-Ⅱ in the observation group were significantly lower than those of the control group[(29.61±6.39)mg/mL vs(56.20±7.62)mg/mL,(61.58±15.80)ng/mL vs(83.29±18.62)ng/mL,(23.60±3.85)ng/mL vs(39.67±5.62)ng/mL)(P<0.05).Conclusion Weishuning combined with pantoprazole can effectively im-prove the clinical symptoms,the function of gastric mucosa and serological indicators of patients with duodenal ulcer,with signifi-cant therapeutic effect.

Weishuning(胃舒宁)pantoprazoleduodenal ulcergastric mucosa functionserological indicators

刘洪岩、杨浩、伍畅

展开 >

松滋市人民医院,湖北栀滋 434200

胃舒宁 泮托拉唑 十二指肠溃疡 胃黏膜功能 血清学指标

2025

辽宁中医杂志
辽宁中医药大学,辽宁省中医药学会

辽宁中医杂志

北大核心
影响因子:0.815
ISSN:1000-1719
年,卷(期):2025.52(1)